Literature DB >> 2996879

Experimental reactivation of equid herpesvirus 1 (EHV 1) following the administration of corticosteroids.

N Edington, C G Bridges, A Huckle.   

Abstract

Eight ponies were experimentally infected with equid herpesvirus 1 (EHV 1) (subtype 1). All animals showed clinical and serological evidence of infection and virus was isolated from nasal swabs and leucocytes. These ponies were kept in isolation for a further three months during which time complement fixing antibody decreased at least four-fold. Following immunosuppression with dexamethasone and prednisolone subtype 1 virus was recovered from six of the eight animals within 14 days. Five of these six ponies were viraemic and three of them shed virus in nasal secretions; only four displayed significant rises in complement fixing antibody and only two in neutralising antibody. Clinical abnormalities were not detected during reactivation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996879     DOI: 10.1111/j.2042-3306.1985.tb02524.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  14 in total

1.  Immunological correlates of vaccination and infection for equine herpesvirus 1.

Authors:  Laura B Goodman; Christine Wimer; Edward J Dubovi; Carvel Gold; Bettina Wagner
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

2.  Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection with EHV-4 or a TK-deletion mutant of EHV-1.

Authors:  D Tewari; J S Gibson; J D Slater; T O'Neill; D Hannant; G P Allen; H J Field
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

3.  Detection of latency-associated transcripts of equid herpesvirus 1 in equine leukocytes but not in trigeminal ganglia.

Authors:  P M Chesters; R Allsop; A Purewal; N Edington
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Asinine herpesvirus genomes: comparison with those of the equine herpesviruses.

Authors:  G F Browning; N Ficorilli; M J Studdert
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

5.  Effective chemotherapy of equine herpesvirus 1 by phosphonylmethoxyalkyl derivatives of adenine demonstrated in a novel murine model for the disease.

Authors:  H J Field; A R Awan
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infection with Equine Herpesvirus-1.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Helen Clare Roberts; Barbara Padalino; Paolo Pasquali; Hans Spoolder; Karl Ståhl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Andrea Carvelli; Romain Paillot; Alessandro Broglia; Lisa Kohnle; Francesca Baldinelli; Yves Van der Stede
Journal:  EFSA J       Date:  2022-01-12

7.  Reinfection and reactivation of equine herpesvirus-1 in the mouse.

Authors:  H J Field; A R Awan; R de la Fuente
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Pathogenesis of equine herpesvirus-1 in specific pathogen-free foals: primary and secondary infections and reactivation.

Authors:  J S Gibson; J D Slater; A R Awan; H J Field
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity.

Authors:  Christiane L Schnabel; Christine L Wimer; Gillian Perkins; Susanna Babasyan; Heather Freer; Christina Watts; Alicia Rollins; Nikolaus Osterrieder; Bettina Wagner
Journal:  BMC Vet Res       Date:  2018-08-22       Impact factor: 2.741

10.  The effect of consignment to broodmare sales on physiological stress measured by faecal glucocorticoid metabolites in pregnant Thoroughbred mares.

Authors:  Martin Schulman; Annet Becker; Stefanie Ganswindt; Alan Guthrie; Tom Stout; Andre Ganswindt
Journal:  BMC Vet Res       Date:  2014-01-17       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.